[go: up one dir, main page]

PE20061417A1 - Metodo para sintetizar 3-cianoquinolinas sustituidas y sus intermediarios - Google Patents

Metodo para sintetizar 3-cianoquinolinas sustituidas y sus intermediarios

Info

Publication number
PE20061417A1
PE20061417A1 PE2006000534A PE2006000534A PE20061417A1 PE 20061417 A1 PE20061417 A1 PE 20061417A1 PE 2006000534 A PE2006000534 A PE 2006000534A PE 2006000534 A PE2006000534 A PE 2006000534A PE 20061417 A1 PE20061417 A1 PE 20061417A1
Authority
PE
Peru
Prior art keywords
alkyl
substituted
ring
halogen
bicycle
Prior art date
Application number
PE2006000534A
Other languages
English (en)
Inventor
Warren Chew
Gloria Karen Cheal
Jacqueline Francesca Lunetta
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37037465&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20061417(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of PE20061417A1 publication Critical patent/PE20061417A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Quinoline Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

REFERIDA A UN METODO PARA PREPARAR 3-CIANOQUINOLINAS SUSTITUIDAS, QUE COMPRENDE HACER REACCIONAR UN COMPUESTO DE FORMULA H-Z-(CH2)n-X, Y UNA 3-CIANOQUINOLINA INTERMEDIARIA DE FORMULA (Ia), EN PRESENCIA DE UN CATALIZADOR ACIDO PARA PRODUCIR UN COMPUESTO DE FORMULA (IIa), DONDE X ES UN ANILLO ARILO BICICLICO O HETEROARILO BICICLICO DE 8 A 12 MIEMBROS, DONDE EL ANILLO HETEROARILO BICICLICO CONTIENE 1 A 4 HETEROATOMOS SELECCIONADOS DE N, O, S, SIEMPRE QUE DICHO ANILLO NO CONTENGA ENLACES O-O, S-S O S-O Y DONDE EL ANILLO PUEDE ESTAR SUSTITUIDO CON HALOGENO, ALQUILO C1-C6, ALQUENILO C2-C6, ENTRE OTROS; A ES UN ANILLO PIRIDILO, PIRIMIDINILO, FENILO, ENTRE OTROS; T ESTA UNIDO A UN CARBONO DE A Y ES -NH(CH2)m-, -O(CH2)m-, -(CH2)m-, ENTRE OTROS; L ES FENILO INSUSTITUIDO O SUSTITUIDO CON HALOGENO, ALQUILO C1-C6, ALQUENILO C2-C6, ENTRE OTROS, O ES HETEROARILO DE 5 O 6 MIEMBROS INSUSTITUIDO O SUSTITUIDO CON HALOGENO, ALQUILO C1-C6, ENTRE OTROS; LV ES UN GRUPO SALIENTE; Z ES NH, O, S, NR; R ES ALQUILO C1-C6; G1, G2, R1 Y R4 SON H, HALOGENO, ALQUILO C1-C6, ALQUENILO C2-C6, ENTRE OTROS; Y ES UN RADICAL DIVALENTE TAL COMO O, -(CH2)a-, ENTRE OTROS; a ES 0 O 1. DICHO METODO EVITA SEPARACIONES CROMATOGRAFICAS Y PERMITE LA OBTENCION DE UN PRODUCTO MAS ESTABLE
PE2006000534A 2005-05-25 2006-05-22 Metodo para sintetizar 3-cianoquinolinas sustituidas y sus intermediarios PE20061417A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US68439105P 2005-05-25 2005-05-25

Publications (1)

Publication Number Publication Date
PE20061417A1 true PE20061417A1 (es) 2007-01-20

Family

ID=37037465

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2006000534A PE20061417A1 (es) 2005-05-25 2006-05-22 Metodo para sintetizar 3-cianoquinolinas sustituidas y sus intermediarios

Country Status (19)

Country Link
US (1) US20060270668A1 (es)
EP (1) EP1883631A1 (es)
JP (1) JP2008545688A (es)
KR (1) KR20080016671A (es)
CN (1) CN101203494A (es)
AR (1) AR053872A1 (es)
AU (1) AU2006249600A1 (es)
BR (1) BRPI0610147A2 (es)
CA (1) CA2609186A1 (es)
CR (1) CR9544A (es)
GT (1) GT200600213A (es)
IL (1) IL187532A0 (es)
NO (1) NO20076067L (es)
PA (1) PA8676201A1 (es)
PE (1) PE20061417A1 (es)
RU (1) RU2007143161A (es)
TW (1) TW200716557A (es)
WO (1) WO2006127207A1 (es)
ZA (1) ZA200710148B (es)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK286975B6 (sk) * 2001-02-24 2009-08-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xantínové deriváty, spôsob ich výroby, farmaceutický prostriedok s ich obsahom a ich použitie
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
RU2405566C9 (ru) 2005-02-03 2012-04-27 Дзе Дженерал Хоспитал Корпорейшн Способ лечения рака, устойчивого к гефитинибу
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
PE20070763A1 (es) 2005-11-04 2007-08-08 Wyeth Corp COMBINACIONES ANTINEOPLASICAS DE UN INHIBIDOR DE mTOR, TRASTUZUMAB Y/O HKI-272
JP5688877B2 (ja) 2005-11-11 2015-03-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 癌疾患の治療用キナゾリン誘導体
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
BRPI0711558A2 (pt) 2006-05-04 2011-11-08 Boeringer Ingelheim Internat Gmbh polimorfos
AU2013202912B2 (en) * 2007-06-08 2016-10-27 Firmenich Incorporated Modulation of chemosensory receptors and ligands associated therewith
US8022216B2 (en) * 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
AU2013203571B2 (en) * 2007-10-17 2016-06-16 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl} -4-(dimethylamino)-2-butenamide and crystalline forms thereof
AU2016225895B2 (en) * 2007-10-17 2018-02-08 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl} -4-)dimethylamino)-2-butenamide and crystalline forms thereof
JP2009215259A (ja) * 2008-03-12 2009-09-24 Ube Ind Ltd ３−ハロゲノ−４−ヒドロカルビルオキシニトロベンゼン化合物の製造方法
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
WO2009151910A2 (en) * 2008-05-25 2009-12-17 Wyeth Combination product of receptor tyrosine kinase inhibitor and fatty acid synthase inhibitor for treating cancer
DK2310011T3 (da) 2008-06-17 2013-10-14 Wyeth Llc Antineoplastiske kombinationer indeholdende hki-272 og vinorelbin
EP2323997B1 (en) 2008-07-31 2017-09-06 Senomyx, Inc. Processes and intermediates for making sweet taste enhancers
SG10202102855RA (en) 2008-08-04 2021-05-28 Wyeth Llc Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine
KR20190016601A (ko) 2008-08-06 2019-02-18 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
BRPI0919288A2 (pt) 2008-09-10 2015-12-15 Boehring Ingelheim Internat Gmbh teriapia de combinação para tratamento de diabetes e condições relacionadas.
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
CN101723854A (zh) * 2008-10-24 2010-06-09 上海特化医药科技有限公司 6-取代氨基-3-氰基喹啉类化合物的制备方法及其中间体
AU2009331471B2 (en) 2008-12-23 2015-09-03 Boehringer Ingelheim International Gmbh Salt forms of organic compound
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
JP5992325B2 (ja) 2009-04-06 2016-09-14 ワイス・エルエルシー 乳癌のための、ネラチニブを活用する治療計画
JP5963672B2 (ja) 2009-07-06 2016-08-03 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｂｉｂｗ２９９２、その塩及びこの活性成分を含む固体医薬製剤の乾燥方法
PH12012501037A1 (en) 2009-11-27 2013-01-14 Boehringer Ingelheim Int Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
CA2797310C (en) 2010-05-05 2020-03-31 Boehringer Ingelheim International Gmbh Glp-1 receptor agonist and dpp-4 inhibitor combination therapy
KR20230051307A (ko) 2010-06-24 2023-04-17 베링거 인겔하임 인터내셔날 게엠베하 당뇨병 요법
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
KR20200003933A (ko) * 2011-03-04 2020-01-10 뉴젠 세러퓨틱스 인코포레이티드 알킨 치환된 퀴나졸린 화합물 및 그것의 사용 방법
CN102718679B (zh) * 2011-03-30 2016-06-08 北京万全阳光医药科技有限公司 一种诺那替尼关键中间体的制备方法
CN102718749A (zh) * 2011-03-30 2012-10-10 北京德众万全药物技术开发有限公司 抗肿瘤药物诺那替尼的制备方法
WO2012155339A1 (zh) 2011-05-17 2012-11-22 江苏康缘药业股份有限公司 4-苯胺-6-丁烯酰胺-7-烷醚喹唑啉衍生物及其制备方法和用途
ES2713566T3 (es) 2011-07-15 2019-05-22 Boehringer Ingelheim Int Derivado de quinazolina dimérico sustituido, su preparación y su uso en composiciones farmacéuticas para el tratamiento de la diabetes de tipo I y II
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
EP4151218A1 (en) 2012-05-14 2023-03-22 Boehringer Ingelheim International GmbH Linagliptin, a xanthine derivative as dpp-4 inhibitor, for use in the treatment of sirs and/or sepsis
US20130303462A1 (en) 2012-05-14 2013-11-14 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor in podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
EP3593648B1 (en) 2012-08-06 2021-07-14 Firmenich Incorporated Sweet flavor modifier
CN103588755B (zh) * 2012-08-17 2016-06-22 正大天晴药业集团股份有限公司 Neratinib的制备方法
AU2014216178B2 (en) 2013-02-15 2018-06-28 KALA BIO, Inc. Therapeutic compounds and uses thereof
JO3155B1 (ar) 2013-02-19 2017-09-20 Senomyx Inc معدِّل نكهة حلوة
EP2958895B1 (en) 2013-02-20 2020-08-19 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
CN103265530A (zh) * 2013-06-14 2013-08-28 苏州明锐医药科技有限公司 来那替尼的制备方法
CA2928658A1 (en) 2013-11-01 2015-05-07 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
US9242965B2 (en) 2013-12-31 2016-01-26 Boehringer Ingelheim International Gmbh Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors
EP3110449B1 (en) 2014-02-28 2023-06-28 Boehringer Ingelheim International GmbH Medical use of a dpp-4 inhibitor
CN105367552A (zh) 2015-01-09 2016-03-02 苏州晶云药物科技有限公司 来那替尼马来酸盐的新晶型及其制备方法
CN105461689B (zh) * 2015-05-19 2018-12-04 上海麦步医药科技有限公司 一种表皮生长因子受体(egfr)抑制剂来那替尼的新型制备方法
CN105085485B (zh) * 2015-08-21 2017-08-29 哈尔滨珍宝制药有限公司 一种来那替尼的制备方法
CN105330646B (zh) * 2015-12-04 2019-05-24 上海勋和医药科技有限公司 一种抗肿瘤药马来酸来那替尼的制备方法
WO2017211979A1 (en) 2016-06-10 2017-12-14 Boehringer Ingelheim International Gmbh Combinations of linagliptin and metformin
CN105949176B (zh) * 2016-06-24 2018-10-26 浙江海正药业股份有限公司 一种来那替尼的纯化方法
US20200308141A1 (en) 2016-06-27 2020-10-01 Pliva Hrvatska D.O.O. Solid state forms of neratinib and salts thereof
CN106220560A (zh) * 2016-07-27 2016-12-14 华侨大学 一种多取代喹啉衍生物的制备方法
CA3036340A1 (en) 2016-09-08 2018-03-15 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
CA3036065A1 (en) 2016-09-08 2018-03-15 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
AU2017324713B2 (en) 2016-09-08 2020-08-13 KALA BIO, Inc. Crystalline forms of therapeutic compounds and uses thereof
EP3700889A4 (en) 2017-11-20 2020-09-02 Teligene Ltd. (E) -N- (3-CYANO-7-ETOXY-4 - ((4-PHENOXYPHENYL) AMINO) QUINOLIN-6-YL) -4- (DIMETHYLAMINO) BUT-2-ENAMIDE AND THEIR CRYSTALLINE FORMS SALTS
CN108285421A (zh) * 2018-01-26 2018-07-17 黑龙江鑫创生物科技开发有限公司 一种微通道反应器合成拉帕替尼中间体的方法
CN110357854A (zh) * 2018-03-26 2019-10-22 江苏创诺制药有限公司 一种来那替尼的制备方法
CN108373467A (zh) * 2018-04-27 2018-08-07 江苏创诺制药有限公司 来那替尼游离碱晶型及制备方法
CN112703193A (zh) 2018-08-07 2021-04-23 弗门尼舍公司 5-取代的4-氨基-1H-苯并[c][1,2,6]噻二嗪2,2-二氧化物及其制剂和用途
CN109320686B (zh) * 2018-08-29 2021-06-08 华南理工大学 一种聚异脲类聚合物及其制备方法和应用
CN112679473B (zh) * 2019-10-18 2024-03-05 四川科伦药物研究院有限公司 来那替尼中间体晶体、制备方法及其用途
CN111875539B (zh) * 2020-07-15 2022-06-21 苏中药业集团股份有限公司 一种egfr类分子靶向抗肿瘤药物的制备方法
CN111848582A (zh) * 2020-08-19 2020-10-30 重庆医科大学 制备表皮生长因子受体抑制剂来那替尼有关物质的方法
CN111848581B (zh) * 2020-08-19 2021-08-10 昆明学院 3-氰基-4-苯胺基-6-氨基喹啉衍生物的制备方法
KR102713340B1 (ko) * 2022-11-08 2024-10-02 경희대학교 산학협력단 고리화첨가 반응과 고리축소 반응의 연속 반응을 이용한 피롤로[1,2-a]퀴놀린의 제조방법

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6002008A (en) * 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
UA73073C2 (uk) * 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
US6297258B1 (en) * 1998-09-29 2001-10-02 American Cyanamid Company Substituted 3-cyanoquinolines
JP4548642B2 (ja) * 1998-09-29 2010-09-22 アメリカン・サイアナミド・カンパニー プロテインチロシンキナーゼインヒビターとしての置換３−シアノキノリン
US6288082B1 (en) * 1998-09-29 2001-09-11 American Cyanamid Company Substituted 3-cyanoquinolines
US6384051B1 (en) * 2000-03-13 2002-05-07 American Cyanamid Company Method of treating or inhibiting colonic polyps
UA77200C2 (en) * 2001-08-07 2006-11-15 Wyeth Corp Antineoplastic combination of cci-779 and bkb-569
CN1330627C (zh) * 2002-02-05 2007-08-08 惠氏公司 N－酰基－2－氨基－4－烷氧基－5－硝基苯甲酸类化合物的合成方法
CL2004000016A1 (es) * 2003-01-21 2005-04-15 Wyeth Corp Compuesto derivado de cloruro de 4-amino-2-butenoilo o una sal farmaceuticamente aceptable del mismo; procedimiento para preparar dicho compuesto, util como intermediario en la sintesis de compuestos inhibidores de proteina quinasa tirosina.
MXPA06001590A (es) * 2003-08-19 2006-05-19 Wyeth Corp Proceso para la preparacion de 4-amino-3-quinolincarbonitrilos.
US7365203B2 (en) * 2003-09-15 2008-04-29 Wyeth Process for the synthesis of 6-amino-4-(3-chloro-4-fluoro-phenylamino)-7-ethoxy-quinoline-3-carbonitrile
US7399865B2 (en) * 2003-09-15 2008-07-15 Wyeth Protein tyrosine kinase enzyme inhibitors
MXPA06002846A (es) * 2003-09-15 2006-06-14 Wyeth Corp Quinolinas sustituidas como inhibidores de la enzima de la proteina tirosina cinasa.
CN1930128A (zh) * 2004-01-16 2007-03-14 惠氏公司 受体酪氨酸激酶抑制剂的喹啉中间体及其合成

Also Published As

Publication number Publication date
BRPI0610147A2 (pt) 2010-06-01
AR053872A1 (es) 2007-05-23
CA2609186A1 (en) 2006-11-30
PA8676201A1 (es) 2009-03-31
ZA200710148B (en) 2008-09-25
WO2006127207A1 (en) 2006-11-30
CR9544A (es) 2008-03-07
KR20080016671A (ko) 2008-02-21
TW200716557A (en) 2007-05-01
RU2007143161A (ru) 2009-07-10
AU2006249600A1 (en) 2006-11-30
JP2008545688A (ja) 2008-12-18
CN101203494A (zh) 2008-06-18
GT200600213A (es) 2007-01-12
US20060270668A1 (en) 2006-11-30
EP1883631A1 (en) 2008-02-06
IL187532A0 (en) 2008-03-20
NO20076067L (no) 2007-12-21

Similar Documents

Publication Publication Date Title
PE20061417A1 (es) Metodo para sintetizar 3-cianoquinolinas sustituidas y sus intermediarios
UA93861C2 (uk) Спосіб одержання n-фенілпіразол-1-карбоксамідів та сполука аніліну
PH12013501197B1 (en) Indeno-fused ring compounds
PH12013501196B1 (en) Indeno- fused ring compounds having photochromic properties
CO6321248A2 (es) Derivados de triazol utiles para el tratamiento de enfermedades
PE20130012A1 (es) Derivados de pirazol como inhibidores de jak
EA200971100A1 (ru) Производные фталазинона в качестве ингибиторов поли(адф-рибоза)полимеразы (parp-1)
NO20065494L (no) Fuserte kinolinderivater og anvendelse derav
PE20140975A1 (es) Derivados de imidazopirazina como inhibidores de syk
CY1112914T1 (el) Υποκατεστημενα παραγωγα ινδολυλ αλκυλ αμινης ως νεοι αναστολεις των αποακετυλασων ιστονης
ECSP088145A (es) Derivados bicíclicos como inhibidores de la cinasa p38
CO6210698A2 (es) Compuestos quimicos 637:piridopirimidindionas como inhibidores de pde4
CY1112102T1 (el) Υποκατεστημενες πυριμιδοδιαζεπινες χρησιμες ως αναστολεις plk1
CY1109727T1 (el) Παραγωγα ν3 αλκυλιωμενου βενζιμιδαζολιου ως αναστολεις μεκ
CO6450621A2 (es) Sulfonamidas nematocidas
EA201171062A1 (ru) Алкиламидные соединения и их применение
CY1110010T1 (el) Πυριδιναμινοσουλφονυλ υποκατεστημενα βενζαμιδια ως αναστολεις κυτοχρωματος ρ450 3α4 (cyp3a4)
DE602006006850D1 (de) Als modulatoren von dopamin-d3-rezeptoren geeignete azabicyclo-(3,1,0)-hexan-derivate
MA32192B1 (fr) Composés dérivés d'azétidines, leur préparation et leur application en thérapeutique
PE20090372A1 (es) Derivados de indolinonas como inhibidores de quinasas especificas del ciclo celular
PE20070041A1 (es) Amidas de acido pirazolcarboxilico
NO20081621L (no) Tetrahydrokinoliner, syntese og intermediater
MX372721B (es) Ánalogos halogenados de agentes antifi-broticos.
PA8676301A1 (es) Metodos para sintetizar derivados de 6-alquilaminoquinolina
ECSP088151A (es) Diazepinoquinolinas, sintesis de las mismas, e intermediarios para obtenerlas

Legal Events

Date Code Title Description
FC Refusal